Cargando…

The combination of HDAC and aminopeptidase inhibitors is highly synergistic in myeloma and leads to disruption of the NFκB signalling pathway

There is a growing body of evidence supporting the use of epigenetic therapies in the treatment of multiple myeloma. We show the novel HDAC inhibitor CHR-3996 induces apoptosis in myeloma cells at concentrations in the nanomolar range and with apoptosis mediated by p53 and caspase pathways. In addit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smith, Emma M., Zhang, Lei, Walker, Brian A., Davenport, Emma L., Aronson, Lauren I., Krige, David, Hooftman, Leon, Drummond, Alan H., Morgan, Gareth J., Davies, Faith E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2013
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4627310/ https://www.ncbi.nlm.nih.gov/pubmed/26015393

Ejemplares similares

Bortezomib (Velcade™) in the Treatment of Multiple Myeloma
por: Field-Smith, Antonia, et al.
Publicado: (2006)

Natural chalcones as dual inhibitors of HDACs and NF-κB
por: ORLIKOVA, B., et al.
Publicado: (2012)

Characterization of a Novel Mouse Model of Multiple Myeloma and Its Use in Preclinical Therapeutic Assessment
por: Fryer, Rosemary A., et al.
Publicado: (2013)

Hsp70 inhibition induces myeloma cell death via the intracellular accumulation of immunoglobulin and the generation of proteotoxic stress()
por: Zhang, Lei, et al.
Publicado: (2013)

HDAC-mediated Deacetylation of NF-κB is Critical for Schwann cell Myelination
por: Chen, Ying, et al.
Publicado: (2011)

Sumoylation of HDAC2 promotes NF-κB-dependent gene expression
por: Wagner, Tobias, et al.
Publicado: (2015)

Aminopeptidase Expression in Multiple Myeloma Associates with Disease Progression and Sensitivity to Melflufen
por: Miettinen, Juho J., et al.
Publicado: (2021)

The NF-κB Activating Pathways in Multiple Myeloma
por: Roy, Payel, et al.
Publicado: (2018)

Targeting NF-κB Signaling for Multiple Myeloma
por: Wong, Ada Hang-Heng, et al.
Publicado: (2020)

Synergistic interaction between HDAC and MCL-1 inhibitors through downregulation of BCL-XL in multiple myeloma
por: Schneller, Anja, et al.
Publicado: (2021)

Aminopeptidases
por: Sanz, Yolanda
Publicado: (2007)

Phosphonic Acid Analogues of Phenylglycine as Inhibitors of Aminopeptidases: Comparison of Porcine Aminopeptidase N, Bovine Leucine Aminopeptidase, Tomato Acidic Leucine Aminopeptidase and Aminopeptidase from Barley Seeds
por: Wanat, Weronika, et al.
Publicado: (2019)

Understanding the interplay between the proteasome pathway and autophagy in response to dual PI3K/mTOR inhibition in myeloma cells is essential for their effective clinical application
por: Aronson, L I, et al.
Publicado: (2013)

Targeting the Non-Canonical NF-κB Pathway in Chronic Lymphocytic Leukemia and Multiple Myeloma
por: Burley, Thomas A., et al.
Publicado: (2022)

The evolving role and utility of off-label drug use in multiple myeloma
por: Stoeckle, James H, et al.
Publicado: (2021)

HDAC7 Activates IKK/NF-κB Signaling to Regulate Astrocyte-Mediated Inflammation
por: Ye, Jinwang, et al.
Publicado: (2022)

Aminopeptidase N
por: Turner, Anthony J.
Publicado: (2013)

MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma
por: Qiang, Ya-Wei, et al.
Publicado: (2018)

CIK Cells and HDAC Inhibitors in Multiple Myeloma
por: Stephan, David, et al.
Publicado: (2017)

NFκB signaling in T cell memory
por: Daniels, Mark A., et al.
Publicado: (2023)

USP4 inhibits p53 and NF-κB through deubiquitinating and stabilizing HDAC2
por: Li, Z, et al.
Publicado: (2016)

Aminopeptidase inhibitors bestatin and actinonin inhibit cell proliferation of myeloma cells predominantly by intracellular interactions
por: Grujić, Mirjana, et al.
Publicado: (2002)

The Regulation of NF-κB Subunits by Phosphorylation
por: Christian, Frank, et al.
Publicado: (2016)

The Links between ALS and NF-κB
por: Källstig, Emma, et al.
Publicado: (2021)

Drug Inhibition Profile Prediction for NFκB Pathway in Multiple Myeloma
por: Peng, Huiming, et al.
Publicado: (2011)

Metallo-aminopeptidase inhibitors
por: Mucha, Artur, et al.
Publicado: (2010)

Membrane alanyl aminopeptidase
por: Turner, Anthony J.
Publicado: (2004)

Cytokine receptor IL27RA is an NF-κB–responsive gene involved in CD38 upregulation in multiple myeloma
por: Brownlie, Rebecca J., et al.
Publicado: (2023)

Feline aminopeptidase N is not a functional receptor for avian infectious bronchitis virus
por: Chu, Victor C, et al.
Publicado: (2007)

Molecular profiling in myeloma
por: Pawlyn, Charlotte, et al.
Publicado: (2018)

Polymorphisms of NFκB1 and IκBα and Their Synergistic Effect on Nasopharyngeal Carcinoma Susceptibility
por: Liu, Yehua, et al.
Publicado: (2015)

The genomic features associated with high-risk multiple myeloma
por: Walker, Brian A., et al.
Publicado: (2018)

Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition?
por: Pawlyn, Charlotte, et al.
Publicado: (2018)

HDAC1 and HDAC2 Regulate Oligodendrocyte Differentiation By Disrupting β-Catenin-TCF Interaction
por: Ye, Feng, et al.
Publicado: (2009)

NF-κB fingerprinting reveals heterogeneous NF-κB composition in diffuse large B-cell lymphoma
por: Jayawant, Eleanor, et al.
Publicado: (2023)

Co-inhibition of NF-κB and JNK is synergistic in TNF-expressing human AML
por: Volk, Andrew, et al.
Publicado: (2014)

PPFIBP1 activates NF-κB signaling to enhance chemoresistance of multiple myeloma
por: Deng, Yi, et al.
Publicado: (2023)

B1, a novel HDAC inhibitor, induces apoptosis through the regulation of STAT3 and NF-κB
por: Cheng, Meng-Hsuan, et al.
Publicado: (2017)

NF-κB/HDAC1/SREBP1c pathway mediates the inflammation signal in progression of hepatic steatosis
por: Guo, Yunwei, et al.
Publicado: (2020)

Sodium phenylbutyrate inhibits Schwann cell inflammation via HDAC and NFκB to promote axonal regeneration and remyelination
por: Yadav, Anjali, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ssbvcbnfei2o20oist6suot89c